Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 08/27 03:59:59 pm
89.395 EUR   +5.17%
05:45pDJFDA Approves Amgen's Cholesterol-Lowering Drug Repatha -- Update
05:18p Amgen wins approval for second biotech cholesterol drug
05:05pDJFDA Approves Amgen's Cholesterol Drug
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

04/24/2012 | 03:39pm US/Eastern

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
React to this article
Latest news on SANOFI
05:45pDJFDA Approves Amgen's Cholesterol-Lowering Drug Repatha -- Update
05:18p Amgen wins approval for second biotech cholesterol drug
05:05pDJFDA Approves Amgen's Cholesterol Drug
04:25pDJFDA Approves Amgen's Repatha Cholesterol Drug
02:01p GENZYME : Details Findings in Experimental Autoimmune Encephalomyelitis (Reducti..
07:22a GENZYME : Icahn School of Medicine at Mount Sinai, Genzyme Assigned Patent
04:03a SANOFI : Discuss pharmaceutical market access strategies with MSD, Sanofi and GS..
08/26 SANOFI : Information concerning the total number of voting rights and shares, pr..
08/26 SANOFI : BE AWARE OF DISEASE RISK IN GRAZING LIVESTOCK ; Merial Animal Health ar..
08/25 SANOFI : NAPW Inducts Sandra Koehne, Senior Manager, Merial the Animal Health Di..
Advertisement
Chart
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials